The capture and visualization of insulin injection patterns together with blood glucose data has potential to improve dialogue between patients and HCPs about dose, injection time and missed injections. This may improve glycemic control. The objective of this non-interventional study was to investigate how a connected insulin pen (NovoPen®6) influences glycemic control in patients with T1DM in a real-world setting. Patients were recruited from 12 Swedish diabetes clinics. At baseline patients received a NovoPen®6, which logs time of injection and number of insulin units. HCP visits were conducted according to clinical practice. At each visit, pen data were downloaded at the clinic to support patient-HCP dialogue. Adults with T1DM (n=94) using NovoPen®6 for basal and/or bolus and CGM were included in the analyses. The effect on TIR was based on a 14-day interval after each visit using a linear mixed-effects model. A significant increase in TIR from baseline to after ≥5 HCP visits (median time in study 6 months) of 1.9 hours/day (9.2 to 11.1 hours/day) was found (p=0.0009). Accordingly, significant reduction in time spent in hyper- and L2 hypoglycemia (-1.8 hours/day p=0.003; -0.3 hours/day p=0.005) was observed. There was no change in time in L1 hypoglycemia (p=0.181). These real-world findings in patients with T1DM highlight the potential benefit on glycemic control when accurate connected pen data contribute to patient-HCP dialogue.

graphic
View largeDownload slide
Disclosure

P. Adolfsson: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk A/S, Roche Pharma. Employee; Self; Region Halland. Research Support; Self; Region Halland. N.V. Hartvig: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. A. Kaas: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. N. Nygård Knudsen: Employee; Self; Novo Nordisk A/S. A. Mårdby: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J. Hellman: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi.

Funding

Novo Nordisk A/S

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.